sorry, we can't preview this file
S1 Text -
Table A. Toxicity grading scales for solicited local and systemic adverse events—modified from FDA toxicity grading scale for clinical abnormalities. Table B. Adverse events of special interest relevant to COVID-19. Table C. Potential immune-mediated medical conditions. Fig A. Vaccine regimens and key trial assessments. Table D. Overall summary of solicited and unsolicited adverse events following vaccination of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants 18 to 84 years of age (Safety Analysis Set). Table E. Percentage of all participants (18 to 84 years) experiencing solicited local and systemic adverse events by symptom, vaccination dose, vaccine group, and maximum toxicity grade (Safety Analysis Set). Table F. Percentage of younger adults (18 to 59 years) experiencing solicited local and systemic adverse events by symptom, vaccination dose, vaccine group, and maximum toxicity grade (Safety Analysis Set). Table G. Percentage of older adults (60 to 84 years) experiencing solicited local and systemic adverse events by symptom, vaccination dose, vaccine group, and maximum toxicity grade (Safety Analysis Set). Table H. Unsolicited adverse events by system organ class and preferred term reported in 1% or more participants in any group through 35 days after first vaccination (Safety Analysis Set).
(DOCX)